<DOC>
	<DOCNO>NCT00002492</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine cisplatin doxorubicin treat patient soft tissue sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response patient resectable soft tissue sarcoma extremity treat neoadjuvant intra-arterial cisplatin IV doxorubicin follow limb-sparing procedure amputation , adjuvant IV cisplatin IV doxorubicin , radiotherapy . II . Determine chemotherapeutic response tumor specimens patient treated regimen . OUTLINE : Neoadjuvant chemotherapy : Patients undergo arterial cannulation follow cisplatin intra-arterially 4 hour day 1 doxorubicin IV ( begin 15 minute completion cisplatin infusion ) day 1-3 . Treatment continue every 3 week 2 course absence unacceptable toxicity . Patients undergo amputation limb-sparing wide excision , feasible , approximately 4 week second course . If surgery schedule time logistical reason , third course may administer . Patients estimate tumor kill least 50 % receive adjuvant chemotherapy outline . Patients undergo limb-sparing wide excision receive post-operative radiotherapy outline . Adjuvant chemotherapy : Beginning 3-4 week surgery , patient receive cisplatin IV 4 hour day 1 doxorubicin day 1-3 . Treatment continue every 3 week 4 course absence disease progression , stable disease , unacceptable toxicity . Patients undergo radiotherapy receive final 3 course chemotherapy completion radiotherapy . Post-operative radiotherapy : Beginning first postoperative chemotherapy course within 8 week surgery , patient receive radiotherapy 5 day week 7-8 week . An interstitial implant use iridium Ir 192 may use administer final dos radiotherapy . PROJECTED ACCRUAL : A total 40 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis intermediate highgrade soft tissue sarcoma extremity amenable limbsparing procedure amputation Buttocks shoulder lesion allow artery available cannulation No metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine clearance least 60 mL/min Cardiovascular : Ejection fraction least 50 % MUGA scan No history congestive heart failure severe angina pectoris Other : No prior malignancy except basal cell skin cancer carcinoma situ cervix Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage I adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
</DOC>